Estrogen Therapy Boosts Transgender Women's Brains

Taking estrogen after gender-affirming surgery improves brain connections key to memory, learning, and emotion in transgender women, a new study finds.

Not only does this suggest that trans women should keep up hormone therapy post-op, but it also underscores the deep connection between hormones and brain connectivity.

After having bottom surgery, removing the testicles, trans women experience the same symptoms that post-menopausal women do, such as hot flashes and night sweats.

The discovery, made by scientists at McMaster University in Ontario, Canada, and at the Hospital de Clínicas de Porto Alegre in Brazil, suggests that estrogen therapy may benefit the brains of trans women and post-menopausal women alike.

As research advances, we are discovering more and more how central hormones are to many physical processes - and how interconnected these systems are.

The hormone or endocrine system plays a key role in instigating everything from how we process food to how stress affects the body and even our heartbeats.

And the new research sheds light on how sex hormones affect the brain, too.

For trans women, gender-affirming surgery can do wonders to dispel lifelong dysphoria, in turn improving mental health and overall quality of life.

As the trans community and trans issues are finally becoming more socially accepted, doctors have seen a swell in the number of people seeking and having gender-affirming operations.

In the case of trans women, a complete transition means removing the testicles and penis - and with them the production center for male hormones.

Orchiectomy for Transgender Women: What to Expect  Warning, this link contains explicit diagrams.

Prior to surgery, many trans women take estrogen - in addition to testosterone blockers and progesterone, in many cases - to encourage their transition.

These hormones have a four-part effect on trans women's bodies and minds.

An infusion of estrogen, coupled with falling testosterone levels, can alter the way a trans woman senses and feels things, redistribute fat, trigger breast growth, change the skin, may trigger the emotional roller coaster of simulated puberty, change hair growth, sex organs and sexuality and more.

There are two categories of fairly clear but poorly understood effects of hormone therapy's effects on the brain: the quick change in how women perceive sensory information and in the emotional changes that some trans women experience.

But the new study reveals one of the mechanisms that may be at play - namely, communication between brain regions through the thalamus.

The researchers recruited 18 transgender women who had undergone complete transition surgeries, including the removal of testicles, stopping their male hormone production.

They all went off the estrogen therapies they'd taken before surgery for a month, were given MRIs to asses their brain activity, then resumed estrogen.

After another two months (60 days), they underwent another MRI.

The researchers saw that, while the women were on estrogen, a region of the brain called the thalamus was much more active...................more

This finding is a great advance for the neuroendocrinology sciences,' said lead researcher Dr. Maiko Abel Schneider of McMaster University in Hamilton, Ontario, Canada.

http://tinyurl.com/y46wgwpu

Virtual Medicine Conference

About the Course Director

Brennan Spiegel, MD, MSHS, is Director of Health Services Research for Cedars-Sinai Health System. He directs the Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), a multidisciplinary team that investigates how digital health technologies – including wearable biosensors, smartphone applications, and virtual reality – can strengthen the patient-doctor bond, improve outcomes and save money. Dr. Spiegel has published numerous best-selling medical textbooks, editorials and more than 170 articles in peer-reviewed journals. He is listed in the Onalytica "Top 100 Influencer" lists for digital health (No. 13) and virtual reality (No. 14). His team's digital health research has been featured by major media outlets, including Bloomberg, the Boston Herald, Forbes, Huffington Post, LA Times, Mashable, NBC News, NPR, PBS, and Reuters. His virtual reality research won the 2017 “Webby Award” for best technology on the internet.

Good morning.  Today's post is a live stream from Cedar's Sinai Medical Center. It is in a virtual reality setting sponsored by Samsung VR.  If you have a headset put it on.  If not you can still see the VR stream live and look throughout the conference room.

Not so far in the future, doctors might prescribe a virtual beach vacation to calm aches and pains, in lieu of taking a pill. Insurance companies might offer scenic tours of Icelandic fjords to lower blood pressure, instead of doubling up on drugs. Psychiatrists might treat social phobia by immersing patients in a virtual dinner party.

It’s starting to happen right now because of virtual reality – the mind-bending technology that offers immersive, multisensory environments that nudge our brains into thinking we are somewhere else.

Virtual Medicine is a two day symposium that convenes the brightest minds in therapeutic VR. Attendees learn from case studies, didactic lectures, patient vignettes, and VR demos.

Virtual Reality is beginning to impact treatment protocols. There are many clinical studies in progress.

Today's presentation Virtual Medicine Conference an excellent presentation focused mostly on behavioral health and presented as a new medium for treating pain, anxiety, depression and other neuropsychiatric disorders. Other possible uses are for phobias, PTSD, Addiction, Acute anxiety disorder, and others.

Virtual Reality in Medical Education

The use of VR in Surgery for teaching and patient education

VR taken individually offers a breakthrough for all these applications.  When coupled with artificial intelligence and bots (automatic chats) for questions and answers it offers an exponential gain in treatment for remote diagnosis and conversation with patients.

A “robot” doctor told a patient he was dying. It might not be the last time. - Vox

This is the future of care for many patients with limited access.

The rapid influx of advanced technology is changing the practice of medicine — at times for the better, but sometimes for the worse. Nowhere is this more apparent than a story where a physician told a fatally ill man in a Fremont, California, hospital that he was dying via video chat on a screen attached to a robot. The news should serve as a wake-up call to the medical establishment on the limits of technology.

The patient, 78-year-old Ernest Quintana, was sitting in his hospital room when a “telepresence robot” — or a mobile robot with a video screen that live-streams a physician in another location — rolled in and informed him that there was nothing that could be done to treat him. Quintana, who had chronic obstructive pulmonary disease, was with his granddaughter and a nurse when he was told his options for managing pain at the end of his life. The granddaughter, shocked at this bombshell dropped from a disembodied robot, filmed part of the encounter, which subsequently went viral online. Mr Quintana died the following day.

The fact that a patient and their family member were delivered devastating news via a telepresence robot is a rightfully shocking episode that runs counter to much of what many of the prophets of the digital revolution in medicine have been preaching. It has confirmed the worst fears of many patients and doctors that technology might increase the distance between physicians and patients during their most vulnerable moments. As a cardiologist training in advanced heart failure who frequently has such conversations with patients — and knowing just how complex and emotionally fraught these moments can be — I am not surprised that the patient and his granddaughter reacted with horror.

Yet a knee-jerk reaction may distract us from looking at the big picture. Just like any medical technology, digital health can be an excellent tool for better, patient-centered care. But it also comes with risks that could erode the practice of medicine, especially for patients who might already have limited access to health care resources and physicians.  However, we cannot allow digital health to take over, it remains one more tool in treating patients, not an endpoint.

The human factor cannot be denied. A cold unfeeling machine is not the same even though a human face is present. Even with a two way video feed certain emotions are not palpable.

A patient expects a human being with whom to interact, either good news or bad news. Technology, artificial intelligence will not replace 'presence'. Even virtual reality probably cannot replace the physical presence of a physician or nurse.

Many in the public and the physician community are skeptical about whether the digital health revolution can bridge the gap between patients and doctors. While I consider myself one of the cautious optimists, the fact is that the way our current health system is designed — and, especially, how we pay for it — digital health innovations could very well stretch the widening gulf between patients and their doctors.

Given that our health system continues to reimburse based mostly on the volume of medical services delivered rather the quality of the care or the patients’ experience, technology will only be deployed so that health systems squeeze their physicians and nurses for every last dollar they can eke out of them. And if the doctor shortage in America’s rural areas continues, scenes such as the one in Mr Quintana’s room may be repeated in the lowest-income communities.

The reason I remain hopeful is actually because of another important side of Mr Quintana’s story. Earlier in the day, a female physician, who was described by the granddaughter as “very sweet,” visited the patient. The content of what this physician said was very similar to what the robo-doctor said, but there was an important difference. She held his hand, explaining the same grim news in a much more humane way.

A “robot” doctor told a patient he was dying. It might not be the last time. - Vox:

Eye Exam Detects Signs of Alzheimer's Disease

The new research is a "small step forward," said Dr. Richard Isaacson, director of the Alzheimer's Prevention Clinic at NewYork-Presbyterian/Weill Cornell Medicine.

"But future studies need to focus on earlier stages of the disease," Isaacson said in an email. "We already have more definitive ways to diagnose dementia due to Alzheimer's, but we need to see if OTCA can be a useful cost-effective screening test for pre-symptomatic Alzheimer's."

 Using an ultrasensitive scanning technique, researchers can detect signs of Alzheimer's disease in the tiny blood vessels at the back of the eye, according to a new report.

Duke University researchers found that these small retinal blood vessels were altered in patients with Alzheimer's disease, but in not in those with mild cognitive impairment (MCI) or those with no signs of mental decline.

"Among the folks who had Alzheimer's there was a significant reduction in the density of the blood vessels in the superficial layer of the retina compared to controls and those with mild cognitive impairment," said Dr. Dilraj Grewal, an associate professor of ophthalmology at the Duke Eye Center. "We also found a reduction in the thickness of (of a specific layer of the retina) in Alzheimer's patients compared to controls and those with mild cognitive impairment."

The findings were reported March 11 online in Ophthalmology Retina, a publication of the American Academy of Ophthalmology.

"The retina is an extension of the brain," Grewal said. "And it's thought that changes that occur in the brain are mirrored in the retina. With any neurodegenerative disease, you lose nerve tissue. Along with a measurable loss of brain volume, there's a loss of the vasculature that supplies the brain. And because the retina is part of the central nervous system, the same changes occur there."

Practical Essentials

The current diagnosis of Alzheimer disease is made by clinical, neuropsychological, and neuroimaging assessments. Routine structural neuroimaging evaluation has long been based on nonspecific features such as atrophy, which is a late feature in the progression of the disease. More recently, a variety of imaging modalities, including structural and functional magnetic resonance imaging (MRI) and positron emission tomography (PET) studies of cerebral metabolism, have shown characteristic changes in the brains of patients with Alzheimer disease in prodromal and even presymptomatic states. ^[1, 2, 3]

Alzheimer disease was first described in 1907 by Alois Alzheimer. From its original status as a rare disease, Alzheimer disease has become one of the most common diseases in the aging population, ranking as the fourth most common cause of death. Alzheimer disease is a progressive neurodegenerative disorder characterized by the gradual onset of dementia. The pathologic hallmarks of the disease are beta-amyloid (Aβ) plaques, neurofibrillary tangles (NFTs), and reactive gliosis. ^[4, 5, 6] (See the images below.)

fMRI revealing changes from Alzheimers Disease

Left Healthy Brain Right Alzheimer Brain  

                          

Coronal, T1-weighted magnetic resonance imaging (MRI) scan in a patient with moderate Alzheimer disease. Brain image reveals hippocampal atrophy, especially on the right side.

Eye Exam Detects Signs of Alzheimer's Disease: Using an ultrasensitive scanning technique, researchers can detect signs of Alzheimer's disease in the tiny blood vessels at the back of the eye, according to a new report.

Retinal fundus photography

Retina Fundus Camera

Using a high-definition eye scan developed especially for the study, researchers detected the crucial warning signs of Alzheimer's disease: amyloid-beta deposits, a buildup of toxic proteins. The findings represent a major advancement toward identifying people at high risk for the debilitating condition years sooner.

In addition to retinal imaging, there may be other ocular findings associated with Alzheimer's disease.

Low levels of amyloid-β and tau proteins, biomarkers of Alzheimer's disease (AD), in eye fluid were significantly associated with low cognitive scores, according to a new study published in the Journal of Alzheimer's Disease. Led by researchers at Boston Medical Center, the study is the first to connect these known AD protein biomarkers in the eye to mental status. These findings indicate that proteins in the eye may be a potential source for an accessible, cost-effective test to predict future Alzheimer's disease.

https://www.hindawi.com/journals/joph/2018/8538573/

https://www.ncbi.nlm.nih.gov/pubmed/25095818

https://www.sciencedirect.com/science/article/abs/pii/S0304394007002492

Drug Pricing |

For years, American patients have suffered under a drug-pricing system that provides generous incentives for innovation, while too often failing to deliver important medications at an affordable cost. We have access to the greatest medicines in the world, but access is meaningless without affordability.

The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs 

• Fact Sheet: 100 Days of Results: President Trump’s American Patients First Blueprint - PDF
• Report on 100 Days of Action on the American Patient First Blueprint - PDF

The Trump blueprint has already made significant gains in controlling and perhaps reversing costs of pharmaceutical benefits.

In an address to the American Medical Association, Alex Azar, head of the Dept of Health and Human Services, had this opening remark,

"The first principle of our vision for value-based healthcare is about empowering patients—but we are fully aware this cannot be done without empowering physicians, too. So I want you all to imagine a system where patients are finally in the driver’s seat, free to work with physicians who have been empowered as navigators of the best options for their patient, rather than navigators of a sea of paperwork."

The mission of HHS is to enhance and protect the health and well-being of every American—and I know that is the mission and vocation of every member of the AMA as well.

That includes the four priorities I’ve chosen as Secretary:  1. combating the opioid crisis, 2. reforming the individual insurance market,  3. lowering the price of prescription drugs, and 4.  transforming our healthcare system into one that pays for value.

HHS has identified four challenges in the American drug market: • High list prices for drugs • Seniors and government programs overpaying for drugs due to lack of the latest negotiation tools • High and rising out-of-pocket costs for consumers • Foreign governments free-riding of American investment in innovation goal of the blueprint was very clear: bringing down prescription drug prices and patient out-of-pocket costs. We laid out dozens of possible actions in the blueprint, many of which will entail some disruption to existing industry players.

That’s why we laid out the blueprint in a deliberative way. We want to disrupt how drugs are priced in America because that system is so deeply broken. But we have to accomplish this goal in a way that minimizes any disruption for patients and providers.

HHS has identified four challenges in the American drug market: • High list prices for drugs • Seniors and government programs overpaying for drugs due to lack of the latest negotiation tools • High and rising out-of-pocket costs for consumers • Foreign governments free-riding of of American investment in innovation Under President Trump, HHS has proposed a comprehensive blueprint for addressing these challenges, identifying four key strategies for reform: • Improved competition • Better negotiation • Incentives for lower list prices • Lowering out-of-pocket costs HHS’s blueprint encompasses two phases: 1) actions the President may direct HHS to take immediately and 2) actions HHS is actively considering, on which feedback is being solicited.Last fall, the President put forth a model for overhauling how Medicare pays for physician-administered drugs, in Medicare Part B fee-for-service.

Today’s Part B status quo is totally unacceptable: America pays almost twice as much, and sometimes five or six times as much, as other wealthy countries pay for the most costly physician-administered drugs. Meanwhile, physicians are put in the position of having to acquire and hold these drugs, which are often extremely expensive, risky acquisitions.

Our new International Price Index model, or IPI, is primarily aimed at delivering for American patients a share of the discounts that drug manufacturers currently give to other wealthy countries. Through the advance notice of proposed rulemaking (ANPRM), CMS is seeking feedback on the potential parameters of the IPI Model. The ANPRM can be downloaded from the CMS Newsroom.

Background

Medicare Part B drug expenditures have increased significantly over time. From 2011 to 2016, Medicare FFS drug spending increased from $17.6 billion to $28 billion under Medicare Part B, representing a compound annual growth rate (CAGR) of 9.8 percent, with per capita spending increasing 54 percent, from $532 to $818. Medicare beneficiaries and the Medicare program are also paying more for Part B drugs than international comparators. Based on a HHS analysis comparing Medicare spending for separately payable Part B physician-administered drugs to the prices of those drugs in sixteen other developed economies – Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Ireland, Italy, Japan, Portugal, Slovakia, Spain, Sweden, and United Kingdom – spending in the U.S. was 1.8 times higher. As a result, Medicare beneficiaries and the Medicare program are bearing unnecessary, potentially avoidable costs for Part B drugs.

Currently, Medicare payment for separately payable outpatient drugs in physician offices, hospital outpatient departments, and certain other settings is based on drug manufacturers’ average sales prices in the United States plus a six percent add-on payment (+6 percent), and is subject to the sequestration, which effectively reduces the add-on to +4.3 percent. The dollar amount of the add-on is larger as drug prices increase, which may encourage physicians to prescribe higher-cost drugs and raise beneficiary and program spending.

Stakeholders have stated that the high cost of Part B drugs for treating cancer, rheumatoid arthritis, multiple sclerosis, other immune disorders, and other conditions, may pose a barrier to providers furnishing these therapies and beneficiaries receiving treatment. CMS has heard from many physicians, specialty groups and patient advocates that the high cost of drugs is a growing financial risk for beneficiaries and providers.

The ongoing struggle against rising drug costs continues. These provisions apply only to CMS and Medicare Beneficiaries.  This segment is a considerable portion of users and ignores private payers. That is another story and also needs to be addressed. 

A Letter from American Health Insurance Plans (Matthew Eyles, President and CEO) explores the ramification and cost shifting that could come about by the International Price Index Model .




Drug Pricing | HHS.gov: Blueprint for bringing down the high price of drugs and reducing out-of-pocket costs for the American consumer.

Cystic Fibrosis drug could be made available as early as NEXT MONTH | UK | News | Express.co.uk

BREXIT has invaded the cystic fibrosis space, threatening the health of CF patients in the U.K.

A WONDER drug (ORKAMBI)  could dramatically improve the lives of thousands of Cystic Fibrosis patients may be available to use next month if a funding deadlock is broken, it emerged yesterday.

ORKAMBI has been unavailable for three years since the FDA approved its use in the United States of America. VERTEX developed and distributes Orkambi thanks to a generous donation and a partnership with the Cystic Fibrosis Foundation (USA)

Vertex has been a major player in CF treatment. They also developed the following CF therapeutics

Kalydeco generic name: ivacaftor  class: CFTR potentiators		10
Orkambi generic name: ivacaftor/lumacaftor  class: CFTR combinations	N/A
Symdeko generic name: ivacaftor/tezacaftor  class: CFTR combinations

All of these drugs have a specific indication for the F508 chromosomal deletion affecting the CFTR protein on cell membranes which is a gatway for chloride transfer.

A description of Cystic Fibrosis was noted in the middle ages.

“Woe is the child who tastes salty from a kiss on the brow, for he is cursed and soon must die”.

Cystic Fibrosis drug could be made available as early as NEXT MONTH | UK | News | Express.co.uk:

Heart Disease Morbidity and Mortality Improve drastically

Apple News

In the US in the 1990s, having a heart attack was basically a death sentence for some 20% of the people who suffered one.

The country’s medical community has spent the last three decades or so working on this problem, and experts widely believe the efforts have paid off. Until now, however, researchers with Yale University say there hasn’t been clear evidence to show that the heart-attack death rate has actually fallen.

Eager to fix that, they set out to analyze data from more than 4.3 million Americans aged 65 or older who had suffered heart attacks. All of them were Medicare fee-for-service patients. The data spans from January 1995 to January 2015 and was pulled from 5,680 US hospitals. The results were published on March 15 in the Journal of the American Medical Association Open Network.

Researchers find heart attacks aren't as frequent or deadly for Americans

The numbers are pretty striking. Back in 1995, 20% of the patients whose cases were included in the study died from their heart attacks. By 2014, that number fell to just 12%. Over the same period, the rate of hospitalization for a first-time heart attack dropped by 38%—from 914 to 566 per 100,000 Medicare beneficiary-years. Because the number of people admitted to the hospital after a heart attack dropped, the healthcare costs attributed to heart attacks has decreased, even though hospital costs overall have increased (pdf) in the US over time.

So what led to these significant declines in costs and fatality rates for heart-attack patients? Much of it has to do with a concerted effort on the parts of three national organizations—the Centers for Medicare & Medicaid Services, the American College of Cardiology, and the American Heart Association—to spearhead changes in treatment.

In the 1990s, the health care community established that aspirin and a class of drugs called beta-blockers (used to reduce blood pressure) were some of the best ways to improve chances of survival after a heart attack. Also over the last 30 years, coronary angioplasty has become more widely available. Physicians use this non-surgical procedure to open arteries that are clogged with a buildup of plaque, thus helping blood flow from the heart. It’s a highly effective way to decrease the risk of mortality, far more so than any medication alone.

The researchers also credit lifestyle changes, such as more healthful dieting, for contributing to the decreases in heart-attack hospitalization and mortality rates.

Not everyone in the US has seen these benefits, however. After analyzing data from thousands of hospitals spread across the US, the researchers uncovered issues of disparity. In places where unemployment is high, the risk of death after suffering a heart attack is higher than in areas with a healthy employment rate. The study didn’t have a clear answer for why that’s the case.

This could be due to more uninsured patients, poor access to hospitals with cardiac excellence centers, and lack of timely emergency transportation, and lack of preventive care. The study did not analyze location parameters.

“This is no time to be complacent,” one of the researchers, Harlan Krumholz, told Consumer Affairs. “We document extraordinary gains—but the effort is far from finished. The goal is to one day relegate heart attacks to the history of medicine.”

WOMEN'S PAIN IS DIFFERENT FROM MEN'S—THE DRUGS COULD BE TOO 

MEN AND WOMEN can’t feel each other’s pain. Literally. We have different biological pathways for chronic pain, which means pain-relieving drugs that work for one sex might fail in the other half of the population.

So why don’t we have pain medicines designed just for men or women? The reason is simple: Because no one has looked for them. Drug development begins with studies on rats and mice, and until three years ago, almost all that research used only male animals. As a result, women in particular may be left with unnecessary pain—but men might be too.

Now a study in the journal Brain reveals differences in the sensory nerves that enter the spinal cords of men and women with neuropathic pain, which is persistent shooting or burning pain. The first such study in humans, it provides the most compelling evidence yet that we need different drugs for men and women.  There’s a huge amount of suffering that’s happening that we could solve," says Ted Price, professor of neuroscience at the University of Texas, Dallas, and an author of the Brainarticle. “As a field, it would be awesome to start having some success stories.”

Modern-day pain control is notoriously dismal. Our go-to medicines—opioids and anti-inflammatories—are just new versions of opium and willow bark, substances we’ve used for thousands of years. Although they are remarkably effective in relieving the sudden pain of a broken bone or pulled tooth, they don’t work as well for people with persistent pain that lasts three months or longer. The failure to include sex differences in the search for better pain relief stems in part from flawed but deep-seated beliefs. “[Medical researchers] made the assumption that men and women were absolutely identical in every respect, except their reproductive biology,” says Marianne Legato, a cardiologist who began sounding an alarm in the 1980s about differences in heart attack symptoms among women. She went on to pioneer a new field of gender-specific medicine.

The physiology of pain is just one of many ways that men and women differ, she says. But she isn’t surprised that no sex-specific medicines have emerged. The medical community—including pharmaceutical companies—didn’t appreciate the variation between men and women, including in their metabolisms, immune systems, and gene expression. "If there were differences in how their drugs worked between men and women, they didn’t want to hear about it," she says. New studies must have separate cohorts for pain studies, rather than aggregating it into one data set. 

What is the legacy of gender-blind research? Mogil once emailed a researcher, asking whether a pain drug worked better in men than women. The researcher didn’t know, and couldn’t pursue the question because the data was controlled by the pharmaceutical company. Mogil was left wondering if drugs that looked promising in male-only animal studies might have failed in clinical trials when the results were blended with those in women, depriving men of a viable treatment.

Medicines that could work best for women wouldn’t make it into the pipeline at all when basic science excluded female animals. Price wonders if unresolved pain among women might have led to their higher levels of chronic pain.  

 Amid the promise of "personalized" medicine, with drugs tailored to patients based on genetic sequencing, developing pain medicines for half the population seems like a no-brainer. "Now there’s a whole new frontier opening up in front of our eyes," Price says. 

Pain physiology is poorly understood. We have difficulty  ranking pain from individual to individual,  let alone along gender classification. The proportionality of pain due to purely neuron transmission to the brain (somatic) vs the second brain (gut) and the role of humoral intermediaries. And lastly the patient's perception of pain is not well measured objectively. Indirectly it can be estimated by changes in vital signs (pulse, blood pressure, respiration, pupillary responses, or involuntary somatic muscle responses.

Basic neurophysiological mechanisms of pain and pain control

Women's Pain Is Different From Men's—the Drugs Could Be Too | WIRED: A new study shows clear differences in the biology of how men and women feel pain, a reminder that sex-specific pain medications might benefit us all.

Dr. Weinstein. A surgeon's struggle with mental health.

Doctors are the healers and the helpers. But what happens when it’s the doctors 
who need the healing and the help?

An estimated 300 to 400 doctors die by suicide each year, a rate of 28 to 40 
per 100,000; more than double that of general population (according to a review 
of 10 years of literature on the subject presented at the American Psychiatry 
Association annual meeting in May 2018).

Doctors who die by suicide often have untreated or undertreated depression or 
other mental illnesses, a fact that underscores the need for early diagnosis 
and treatment.

However, the stigma of a mental illness may be too overwhelming for some 
in the medical community to deal with, and they often mask their pain, rather 
than seek help.  That’s why Dr. Michael Weinstein, a surgeon at Thomas 
Jefferson University Hospital, is so very brave.

When his piece was published, Dr. Weinstein couldn’t anticipate the 

response, but said he received an overwhelming number of affirming

 messages from people from all different walks of life. However, 

perhaps most importantly inthis case, he heard from many colleagues in the 

medical field from across the countryand across the world who saw themselves 

in Dr. Weinstein’s story, and no longer felt alone in their own journeys.

“I realize that, from the outside looking in at me, I’m in potentially a position 

of power, of 

influence.  I’m in a world that could be stereotyped as a world that should be strong 

and courageous and infallible,” he said. “Telling a story from that perspective might

both be able to help folks in similar situations.”

Today, Dr. Weinstein is on a new path of healing. He has embraced Buddhist

 philosophy, and has found the practice of mindfulness meditation to be an 

important part of his recovery. 

Listen to him read excerpts from his inspiring essay “Out of the Straight Jacket” 

and listen to his reflections on his journey to date in this very moving 

OC87 Recovery Diaries video. 

EDITOR IN CHIEF: Gabriel Nathan | EDITOR: Glenn Holsten | 

DESIGN: Leah Alexandra Goldstein | PUBLISHER: Bud Clayman